The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analyses of Japanese patients from the PREVAIL trial of enzalutamide (ENZA) in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC).
 
Go Kimura
Honoraria - Astellas Pharma; Bayer Schering Pharma; GlaxoSmithKline; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Junji Yonese
No Relationships to Disclose
 
Takashi Fukagai
No Relationships to Disclose
 
Tomomi Kamba
No Relationships to Disclose
 
Kazuo Nishimura
No Relationships to Disclose
 
Masahiro Nozawa
Consulting or Advisory Role - Astellas Pharma
Research Funding - Astellas Pharma (Inst)
 
Harry H. Mansbach
Employment - Medivation
 
De Phung
Employment - Astellas Pharma
 
Tomasz M. Beer
Consulting or Advisory Role - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; Janssen Research & Development; Medivation
 
Bertrand F. TOMBAL
Leadership - Amgen; Bayer; Ferring; Sanofi
Honoraria - Astellas Pharma; Medivation
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Ferring; Medivation; Sanofi
Speakers' Bureau - Amgen; Bayer; Ferring; Sanofi
Research Funding - Astellas Pharma (Inst)
 
Takeshi Ueda
Other Relationship - Astellas Pharma